Print ISSN:-2249-8176

Online ISSN:-2348-7682

CODEN : PJMSD7

Current Issue

Year 2024

Volume: 14 , Issue: 2

  • Article highlights
  • Article tables
  • Article images

Article Access statistics

Viewed: 126

Emailed: 0

PDF Downloaded: 512


Rajesh, Karthikeyan, Mughilan, Anbukumar, and Baylis: Study the beneficial effects of oxygen blender during cardiopulmonary bypass in reducing lactate levels in patients undergoing open-heart surgery


Introduction

The increase in the serum lactate during Cardio-Pulmonary Bypass (CPB) is well known in patients undergoing open-heart surgery due to various reasons such as peripheral circulatory failure, haemodilution, or high use of inotropic agents.1, 2, 3 In addition to this, the elevated serum lactate levels during the perioperative period have been reported to be well associated with worst outcomes in the postoperative period, including mortality. 4, 5, 6, 7, 8, 9

Previous various studies proved that early postoperative hyperlactatemia was a more sensitive predictor of mortality and morbidity in patients undergoing open-heart surgery under Cardio-Pulmonary Bypass (CPB) than late-onset hyperlactatemia during ICU stay.10 Furthermore, it was also reported that the maximum serum lactate level during open-heart surgery after CPB was significantly associated with low cardiac output state(LCOS) and ICU-free survival days. 11

Following open-heart surgery, early postoperative hyper-lactatemia was associated with inappropriate or excessive oxygen delivery during CPB. 3, 4, 5, 6 Thus, the proper management of CPB could avoid the increase in serum lactate levels.Therefore, the study aims to find out the effects of an oxygen blender on serum lactate levels.

Aim

To find out the beneficial effects of an oxygen blender during cardiopulmonary bypass in reducing lactate levels in patients undergoing open-heart surgery.

Materials and Methods

This Prospective comparative study was done on 150 patients who underwent open-heart surgeries in our Institute from January 2018 to December 2018. Group A-75 patients: with direct oxygen flow without oxygen blender and the serum lactate levels during CPB and postoperative levels and outcomes were monitored. Group B- 75 patients: with oxygen blender. The serum lactate levels during CPB, postoperative levels and outcomes were monitored and both the groups were compared. Ethical committee approval and informed consent were obtained.

Group A 75 patients - the oxygen line is connected directly to the CPB machine without a blender. Baseline serum lactate value in Arterial blood gas (ABG) analysis was noted before induction of anaesthesia after securing arterial line. After starting CPB, another sample is taken. The following sample is after the first cardioplegia administration. Then, every one hour once, Arterial blood gas (ABG) Analysis is done and lactate values are noted. Serum lactate levels at the end of CPB and at the time of arrival to ICU were noted. The following parameters were noted in the postoperative period like mortality, total duration of ventilation, low cardiac output state, respiratory, renal and central nervous system complications and duration of ICU stay.

Table 1

Gas/blood flow ratio chart

Temperature

Cardiac Index /pump flow rate

FIO2

Gas/Blood Flow Ratio

37 C

2.4 L

0.80

1 : 1

34 C

2.2 L

0.70

0.8 : 1

30 C

2.0 L

0.65

0.7 : 1

28 C

1.8 L

0.60

0.6 : 1

22 C

1.6 L

0.50

0.5 : 1

[i] (Ref:Gravlee - Cardiopulmonary bypass principles and practice 4th edition)

Group B 75 patients- Oxygen blender was used per the Gas/ blood flow ratio given in Table 1 . Target Po2 was 150 to 200 mmHg and Pco2 of 40 mmHg and the FIO2 % and flow rates adjusted according to the ABG values. Lactate levels were noted similar to Group A, the postoperative outcome was monitored, and both groups were compared.

Results

Table 2

Age-wise Distribution of Study patients

Age group

Group A

Group B

Total

< 12 years

20 (26.7%)

16 (21.3%)

36 (24%)

Adults

55 (73.3%)

59 (78.7%)

114 (76%)

Total

75

75

150

Among the 150 study population, 36 pediatric patients (24%) and 114 adult patients (76%) were included. In Group A, 26.7% belong to the pediatric age group and 73.3 % belong to the adult age group. In Group B, 21.3% belong to the pediatric age group and 78.7 % belong to the adult age. (Table 2 )

Table 3

Sex wise distribution of study patients

Gender

Group A

Group B

Total

Adult Male

30 (40%)

27 (36%)

57 (38%)

Adult Female

35 (46.7%)

41(54.7%)

76 (50.7%)

Male child

3 (4%)

4 (5.3%)

7 (4.7%)

Female child

7 (9.3)

3 (4%)

10 (6.6%)

Total

75

75

150

In Group A, 40 % (30 patients) of the study population were adult males and 46.7% were adult females. Whereas in Group A, 36 % (27 patients) of the study group were adult males. 54.7% (41 patients) were adult females. In Group A, 4% (3 patients) were male children and 9.3% (7 patients) were female children, whereas in Group B, 5.3% (4 patients) were male children and 4% (3 patients) were female children. (Table 3)   

Table 4

Surgical Procedure wise Distribution of Study patients – congenital heart disease

Procedure

Group A

Group B

Adult male

Adult female

Male Child

Female child

Total

Adult male

Adult female

Male child

Female child

Total

Ostium secundum type (ASD-0S) Atrial septal defect .Pericardial patch closure (PPC)

1

7

1

4

13 (65%)

1

4

2

1

8 (50%)

Sinus venosus type ASD- PPC

0

0

0

1

1

1

0

0

1

2

Ventricular septal Defect (VSD)-PPC

1

1

0

2

3

2

0

0

0

2

Atrio ventricular canal defect (AVCD-VSD)- Intra Cardiac repair (ICR)

0

0

1

0

1

0

0

0

0

0

Tetrology of Fallot

0

0

1

0

1

0

0

0

0

0

Double chambered right ventricle DCRV-VSD-ICR

0

0

0

0

0

0

0

1

0

1

Double outlet right ventricle DORV-VSD-ICR

0

0

0

0

0

0

1

0

0

1

Supra cardiac TAPVC- Total anomolus pulmonary venous connection- ICR

0

0

0

0

0

0

0

0

1

1

Sub mitral aneurysm (SMA) – ICR with Mitral valve replacement

0

0

0

0

0

0

1

0

0

1

Total

2

8

3

7

20

4

6

3

3

16

Ostium Secundum type (ASD-OS) Atrial septal defect. Pericardial patch closure (PPC) contributes the majority of congenital heart disease (CHD) open-heart surgeries done with 65 % (13 cases) in Group A and 50 % (8 cases) in Group B. (Table 4)

Table 5

Surgical procedure wise distribution of study patients– Acquired heart disease

Procedure

Group A

Group B

Adult male

Adult female

Male child

Female child

Total

Adult male

Adult female

Male child

Female child

Total

Mitral valve replacement (MVR)

8

19

0

0

27 (49%)

7

26

0

0

33 (55%)

Aortic valve replacement (AVR)

2

3

0

0

5 (9%)

1

2

0

0

3 (5%)

Double valve replacement (DVR)

4

2

0

0

6 (10%)

4

2

0

0

6 (10%)

ON pump Coronary Artery Bypass Graft surgery (CABG)

12

1

0

0

13 (23%)

10

0

0

0

10 (17%)

MVR + CABG

0

1

0

0

1

0

0

0

0

0

Excision of left atrial myxoma with PPC

0

1

0

0

1

0

1

0

0

1

Pulmonary Thrombo Endarterectomy (PTE)

1

0

0

0

1

0

0

0

0

0

Cardiac transplantation

1

0

0

0

1

0

0

0

0

0

MVR + Tricuspid valve repair

0

0

0

0

0

0

2

0

0

2

Open pericardectomy

0

0

0

0

0

0

1

0

0

1

Hypertrophic Obstructive Cardiomyopathy (HOCM)- Extended septal myectomy

0

0

0

0

0

1

0

0

0

1

Mitral valve repair

0

0

0

0

0

0

1

1

0

2

Total

28

27

0

0

55

23

25

1

0

59

Mitral valve replacement (MVR) contributes the majority of the acquired heart disease surgeries done with 49 % (27 cases) in Group A and 55 % (33 cases) in Group B, followed by the ON pump Coronary Artery Bypass Graft surgery (CABG) with 23 % (13 cases) in Group A and 17 % (10 cases) in Group B with oxygen blender usage (Table 5)

Table 6

Surgicalprocedure wise distribution of study patients- both congenital and acquired

Procedure

Group A

Group B

Adult male

Adult female

Male child

Female child

Total

Adult male

Adult female

Male Child

Female child

Total

Congenital heart surgeries

2

8

3

7

20 (27%)

4

6

3

3

16 (21.3%)

Acquired heart surgeries

28

27

0

0

55 (73%)

23

25

1

0

59 (78.7%)

Total

30

35

3

7

75

27

31

4

3

75

In Group A, 27 % (20 cases) of surgeries done for congenital heart diseases and 73% (55 cases) were done for acquired heart diseases whereas, in Group B, 21.3% (16 cases) of surgeries done for congenital heart diseases and78.7% (59 cases) done for acquired heart diseases (Table 6)

Table 7

Comparison of postoperative outcomes

Postoperative outcome and complications

Group A (75 cases)

%

Group B (75 cases)

%

Mortality

4

5.33

2

2.7

Duration of ventilation (hours- average)

25.17

19.77

ICU stay in days- average

3.5

2

Reintubation

6

8

2

2.7

Pulmonary edema

26

34.7

13

17

Renal failure requiring dialysis

2

2.7

1

1.3

Low cardiac output state (Requiring high inotropes support)

7

9.4

3

4

Stroke/Cerebro vascular accidents

2

2.7

1

1.3

Postoperative cognitive dysfunction

12

22.7

6

8

Others

8

10.7

2

2.7

Totally 4 patients died in Group A, which is 5.33% and the mortality is 2.7% in Group B. Respiratory complications like reintubation rate 8 % in Group A whereas 2.7 % in Group B. Non-fatal non-cardiogenic pulmonary edema rate is 34.7% in Group A whereas 17 % in Group B. post-operative cognitive dysfunction was higher in Group A around 22.7% whereas it was 8 % in Group B. (Table 7)

Table 8

Comparison of lactate values

Arterial blood lactate levels average (mmol/L)

Baseline

CPB- Onset

CPB- 1 hour

CPB- 2 hours

ICU arrival

Group A

0.8

1.2

8.2

11

10.4

Group B

0.8

1.2

5.1

7.2

6.0

Difference

3.1 P = 0.0008

3.8 p<0.0001

4.4 p<0.0001

Group B showed a significant reduction in the serum lactate value at CPB one hour with 3.1 mmol/l reduction, 3.8 mmol/L reduction at 2 hours and 4.4 mmol/L reduction (p value <0.0001 statistically significant) at ICU arrival.(Table 8)

Table 9

Late onset hyperlactatemia

Arterial blood lactate levels average (mmol/L)

6hours after ICU Arrival

Group A

11.2

Group B

7.4

Difference

3.8 (p<0.0001)

Group B showed a significant reduction in the late-onset hyperlactatemia six hours after ICU arrival with 3.8 mmol/L reductions (p-value <0.0001) (Table 9)

Table 10

AverageFiO2and PO2 PCO2 levels

Arterial blood levels average

FiO2 %

PO2 level mmHg average

PCO2 level mmHg average

Group A

100%

406

20

Group B

38%

168

41

Difference

62% (p<0.0001)

238 (p<0.0001)

Average FIO2 of 38 % was enough to maintain PO2 of 168 mm Hg by using the oxygen blender with the flow rates according to Table 1. Group A showed severe hyperoxemia (p-value <0.0001) and hypocarbia, resulting in severe respiratory alkalosis during CPB and severe acidosis in the immediate postoperative period in most of the cases. (Table 10)

Discussion

We have demonstrated, via this prospective cardiac surgery series, that an Average FIO2 of 38% was enough to maintain PO2 of 168 mm Hg by using the oxygen blender with the flow rates according to Table 1. Specifically, we showed that most major complications, including reintubation rate, pulmonary edema, renal complications, stroke, postoperative cognitive dysfunction and mortality, are increased correlating with high lactate levels in Group A.

Cardiopulmonary bypass(CPB) produced various changes in the body hemodynamics. Unfortunately, most of them are harmful to the patients. But many advances during the last few decades targeted towards reducing the harmful effects of CPB on the human body. One of the advancements is the oxygen blender. The function of the blender is to control the FIO2% and oxygen flow rates during CPB, which prevents hyperoxemia and its adverse effects.

Excess oxygen exposure (hyperoxia) induces excessive reactive oxygen species (ROS) production in cell-culture and ischemia-reperfusion experiments. 12, 13, 14 Similarly, hyperoxic reperfusion of ischemic tissues is associated with tissue damage and poor outcomes in some patient populations. 15, 16, 17 During cardiac surgery, anesthesiologists typically ventilate patients with an FIO2 of 1.0 and if we do not use an oxygen blender patient will get 100% oxygen during the entire CB. In normal conditions, approximately 99% of the oxygen in the blood is bound to hemoglobin, and administering oxygen at concentrations higher than those needed to saturate hemoglobin does not increase oxygen content in the blood by a clinically significant amount. It does, however, increase the partial pressure of oxygen in the plasma to supraphysiologic levels. These super-physiologic levels may increase the production of reactive oxygen species (ROS),18 which could induce oxidative stress and lead to organ injury. Oxidative stress causes direct damage to proteins at the cellular level, including deoxyribonucleic acid (DNA) and lipids, resulting in organelle autophagy, cellular apoptosis and necrosis, organ injury and dysfunction, and death. 19

Preclinical studies have also demonstrated that ROS impair endothelial function.20 The endothelium regulates perfusion. Thus, endothelial dysfunction may contribute to the associations among patient oxygenation, oxidative stress, and organ injury following cardiac surgery. The ROCS (Risk of Oxygen during Cardiac Surgery) trial. 21 will test the hypothesis that physiologic oxygenation during surgery will decrease the production of ROS, oxidative damage, and organ injury compared to hyper-oxygenation

Conclusion

We conclude that avoiding hyperoxemia by using an oxygen blender with average FIO2 of 38% is enough to maintain PO2 of 168 mmHg by this study. Serum lactate values reduced significantly in the study Group B with a significant reduction in the serum lactate value at CPB one hour with 3.1 mmol/l reductions, 3.8 mmol/L reductions at 2 hours and 4.4 mmol/L reductions at ICU arrival (p-value <0.00001). Postoperative complications were significantly reduced in the study group B with a 2.7% reduction in mortality, 17.7% decrease in respiratory complications and 14.7% reduction in postoperative cognitive dysfunction.

Optimal use of oxygen blender during CPB as per the calculation to maintain optimal PO2 will significantly improve the postoperative outcomes, as shown in our study. Our study proved that application of an oxygen blender during CPB thereby improving the postoperative results following open-heart surgeries.

Source of Funding

None.

Conflict of Interest

None.

References

1 

DJ O’brien JA Alexander JM Civetta RW Taylor RR Kirby Postoperative management of the adult cardiac surgery patientCritical care. 3rd edn.Philadelphia, PA: Lippincott Williams & Wilkins1997114775

2 

P Demers S Elkouri R Martineau A Couturier R Cartier Outcome with high blood lactate levels during cardiopulmonary bypass in adult cardiac operationAnn Thorac Surg200070620826

3 

JM Maillet PL Besnerais M Cantoni P Nataf A Ruffenach A Lessana Frequency, risk factors, and outcome of hyperlactatemia after cardiac surgeryChest2003123513616

4 

LA Hajjar JP Almeida JT Fukushima A Rhodes JL Vincent EA Osawa High lactate levels are predictors of major complications after cardiac surgeryJ Thorac Cardiovasc Surg2013146245560

5 

M Ranucci G Carboni M Cotza P Bianchi UD Dedda T Aloisio Hemodilution on cardiopulmonary bypass as a determinant of early postoperative hyperlactatemiaPLoS One201510512693910.1371/journal.pone.0126939

6 

KA Plestis JP Gold Importance of blood pressure regulation in maintaining adequate tissue perfusion during cardiopulmonary bypassSemin Thorac Cardiovasc Surg20011321705

7 

N Furushima M Egi Y Nakada D Ono J Araki The association of intraoperative blood lactate concentrations with outcomes in adult cardiac surgery patients requiring cardiopulmonary bypassMasui201463884650

8 

SB Shinde KK Golam P Kumar ND Patil Blood lactate levels during cardiopulmonary bypass for valvular heart surgeryAnn Card Anaesth2005813944

9 

S Svenmarker S Häggmark M Ostman What is a normal lactate level during cardiopulmonary bypass?Scand Cardiovasc J200640530511

10 

E O’connor JF Fraser The interpretation of perioperative lactate abnormalities in patients undergoing cardiac surgeryAnaesth Intensive Care2012404598603

11 

L Mcnicol M Lipcsey R Bellomo F Parker S Poustie G Liu Pilot alternating treatment design study of the splanchnic metabolic effects of two mean arterial pressure targets during cardiopulmonary bypassBr J Anaesth201311057218

12 

C Brueckl S Kaestle A Kerem H Habazettl F Krombach H Kuppe Hyperoxia-induced reactive oxygen species formation in pulmonary capillary endothelial cells in situAm J Respir Cell Mol Biol200634445363

13 

JP Fessel CR Flynn LJ Robinson NL Penner S Gladson CJ Kang Hyperoxia synergizes with mutant bon morphogenic protein receptor 2 to cause metabolic stress, oxidant injury and pulmonary hypertensionAm J Respir Cell Mol Biol201349577887

14 

JD Stoner TL Clanton SE Aune MG Angelos O2 delivery and redox state are determinants of compartment-specific reactive O2 species in myocardial reperfusionAm J Physiol Heart Circ Physiol2007292110916

15 

JH Kilgannon AE Jones E Parrillo RP Dellinger B Milcarek K Hunter Emergency Medicine Shock Research Network I Relationship between supranormal oxygen tension and outcome afte resuscitation from cardiac arrestCirculation201112323271722

16 

Y Liu RE Rosenthal Y Haywood M Miljkovic-Lolic JY Vanderhoek G Fiskum Normoxic ventilation after cardiac arrest reduces oxidation of brain lipid and improves neurological outcomeStroke1998298167986

17 

D Stub K Smith S Bernard Z Nehme M Stephenson JE Bray Air versus oxygen in ST-segmen elevation myocardial infarctionCirculation201513124214350

18 

JP Fessel NA Porter KP Moore JR Sheller Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tensionProc Natl Acad Sci U S A20029926167138

19 

J Chandra A Samali S Orrenius Triggering and modulation of apoptosis by oxidative stressFree Radic Biol Med2000293-432333

20 

H Lum KA Roebuck Oxidant stress and endothelial cell dysfunctionAm J Physiol Cell Physiol2001280471941

21 

MG Lopez M Pretorius MS Shotwell R Deegan SS Eagle JM Bennett The Risk of Oxygen during Cardiac Surgery (ROCS) trial: study protocol for a randomized clinical trialTrials201718129510.1186/s13063-017-2021-5



jats-html.xsl

© 2024 Published by Innovative Publication Creative Commons Attribution 4.0 International License (creativecommons.org)